Advanced CSCC

Long-term
follow-up data

In patients with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation:

Long-term follow-up data for LIBTAYO1-3*

The following data represent a 3-year follow-up in Group 1, and 2-year follow-up for Group 2 and Group 3* Follow-ups for each group are based on time from primary analysis for Study 1540

Tumor response assessment, time to response and duration of response with LIBTAYO
  • *For these long-term data, the predetermined data cutoff date was October 11, 2020.2
  • Based on number of patients with confirmed CR or PR.2
  • Percentages are based on number of patients with confirmed CR or PR. The numerator includes the number of patients whose observed duration of response reached at least the specified time. Patients who did not have the opportunity to reach the specified timepoint were included in the denominator only. Because responses for some patients are ongoing, the percentages at the specified timepoints may increase as data mature.3
  • Adapted with permission from Rischin et al, 2021.2
  • CI=confidence interval; CR=complete response; CSCC=cutaneous squamous cell carcinoma; ICR=independent central review; IQR=interquartile range; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; NE=not evaluable; NR=not reached; ORR=objective response rate; PR=partial response; Q2W=every 2 weeks; Q3W=every 3 weeks.

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1

Long-term follow-up data for Study 1540: Time to response3*

Median TTR for the combined advanced CSCC group was 2.1 months (range, 1.9-3.7)3†


Longer-term follow-up clinical study 1540: time to response

Median time to complete response for combined advanced CSCC group:
11.3 months (range, 1.8-22.8)3†


  • IIFor these long-term data, the predetermined data cutoff date was October 11, 2020.2
  • Based on number of patients with confirmed CR or PR.2

Updated Pivotal Trial Data for LIBTAYO® (cemiplimab-rwlc)

Description
This video provides an update to the original clinical trial data from Study 1540 (EMPOWER-CSCC 1) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May 2020.
Please click here for full Prescribing Information.